Dr. OlgaBezzubova

Partner

Munich + 49.89.20.60.42.200

Olga Bezzubova has more than 20 years of experience in obtaining and defending intellectual property rights for clients in the fields of pharmaceuticals, biotechnology, and diagnostics. Olga is co-leader of the Firm's global patent prosecution practice, leader of the Firm's European life sciences and chemistry patent prosecution group, and Munich IP practice coordinator.

Olga advises on all aspects of patent prosecution and opposition, supplementary protection certificates, patent validity, and infringement. She has experience in developing global IP strategies for established biotech companies and start-ups, as well as managing patent portfolios worldwide. Olga's unique background in physics and biology allows her to counsel clients in matters involving various aspects of cell biology, genomics, proteomics, molecular biology, food science, biopharmaceuticals, and biophysics, as well as emerging technologies at the convergence of biological and physical sciences. Olga has represented clients in highly competitive areas of RNA (ribonucleic acid) interference (RNAi) and CRISPR/Cas gene editing (clustered regularly interspaced short palindromic repeats).

Olga has authored and coauthored numerous publications in the field of molecular genetics and IP.

Experience

  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®).
  • ToolGen defends multi-party opposition at EPO relating to CRISPR/Cas9 gene editing technologyJones Day is acting for ToolGen, Inc. in defense of a multi-party opposition filed at the European Patent Office against its patent rights covering application of the revolutionary CRISPR/Cas9 gene editing technology in biotechnology, medicine, and agriculture.
  • CJ CheilJedang defends German patent infringement action by Japanese competitorJones Day is representing CJ CheilJedang Corporation, a major Korean-based multinational company, in a patent dispute with a Japanese competitor before the courts in Germany.
  • ToolGen seeks patent protection for CRISPR technologyJones Day is prosecuting patent applications and developing a patent portfolio on behalf of ToolGen, Inc. for CRISPR technology.
  • Celgene subsidiary develops patent portfolio for stem cell and biofabric productsOn behalf of Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, Jones Day assisted with patent prosecution strategies and establishing patent portfolios for the stem cell and biofabric products being developed by the company.
  • Speaking Engagements

    • February 7, 2017
      Brexit and the Unitary Patent System, JD Women in IP
    • November 19, 2013
      IP Strategies for Life Science Companies: The New European System, Seminar for France Biotech
    • June 4, 2013
      Divisionals in Europe: Practical Advice
    • March 25, 2013
      Europe's New Unitary Patent and Unified Patent Court: How the introduction of the Unitary Patent and Unified Patent Court will impact your existing patent portfolio
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.